Highly Multiplexed Cell-Based GPCR Assay.

Spectragenetics, Pittsburgh PA

Investigators

Abstract

Project Summary/Abstract Chip-based technologies - e.g. DNA microarrays and next generation sequencing - have profoundly accelerated the pace of biomedical discovery because they are miniaturized, multiplexed, and highly scalable. We will bring these same virtues to cell-based screening against GPCRs, the most prevalent targets of therapeutic drugs to treat mental illness and other diseases and conditions, by applying SpectraGenetics' FAP technology to printed reverse transfection microarrays. The new assay system will detect and quantify the responses of many GPCRs in parallel by interrogating arrayed reverse-transfected mammalian cells that express FAP-tagged receptors. This miniaturized, multiplexed and scalable system will enable diverse GPCR discovery projects, and will dramatically lower the cost-per-target in primary and secondary drug screens, thereby relieving major bottlenecks in the development of new therapeutic molecules.